ANTHERA PHARMACEUTICALS
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2004-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.anthera.com
PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease
- Conditions
- Coronary Artery Disease (CAD)
- First Posted Date
- 2007-04-03
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- Anthera Pharmaceuticals
- Target Recruit Count
- 400
- Registration Number
- NCT00455546
- Locations
- 🇺🇸
Charlotte Cardiovascuar Research, Port Charlotte, Florida, United States
🇺🇸Louisville Cardiology Medical Group, Louisville, Kentucky, United States
🇺🇸United Medical Associates, Binghamton, New York, United States
Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
- Conditions
- Cystic FibrosisExocrine Pancreatic Insufficiency
- Interventions
- Drug: LiprotamaseDrug: Placebo
- First Posted Date
- 2007-03-21
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- Anthera Pharmaceuticals
- Target Recruit Count
- 163
- Registration Number
- NCT00449878
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milwaukee, Wisconsin, United States
Open-Label Phase III Long-Term Safety Trial of Liprotamase
- Conditions
- Cystic FibrosisExocrine Pancreatic Insufficiency
- Interventions
- Drug: Liprotamase
- First Posted Date
- 2007-03-21
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- Anthera Pharmaceuticals
- Target Recruit Count
- 214
- Registration Number
- NCT00449904
- Locations
- 🇺🇸
University of For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Burlington, Vermont, United States
🇺🇸For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States
IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome
- Conditions
- Sickle Cell DiseaseVaso-occlusive CrisisAcute Chest Syndrome
- Interventions
- Other: PlaceboDrug: A-001
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Anthera Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT00434473
- Locations
- 🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States
🇺🇸SUNY Downstate Medical Center, Brooklyn, New York, United States
🇺🇸Duke University Comprehensive Sickle Cell Center, Durham, North Carolina, United States
Oral TheraCLECâ„¢ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency
- Conditions
- Pancreatic InsufficiencyCystic Fibrosis
- Interventions
- Drug: LiprotamaseDrug: Placebo
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2014-10-17
- Lead Sponsor
- Anthera Pharmaceuticals
- Target Recruit Count
- 129
- Registration Number
- NCT00095732
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morgantown, West Virginia, United States